Fig. 1: CONSORT diagram. | npj Breast Cancer

Fig. 1: CONSORT diagram.

From: High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial

Fig. 1

*Three ineligible patients were randomized by mistake: two patients with a tumor that showed a sporadic-like profile, but that at the same time was positive for BRCA1 promoter hyper-methylation were randomized to the conventional chemotherapy arm. One received ddAC-only, the other ddAC-CP. One patient was found to be metastatic at baseline and was randomized to the high-dose arm. These patients remained part of the ITT analysis.

Back to article page